Seres Therapeutics, Inc. - COMMON STOCK (MCRB)

Historical Holders from Q2 2015 to Q2 2025

Symbol: MCRB on Nasdaq
Type / Class: Equity / COMMON STOCK
Shares outstanding: 170,403,883
All holders as of 30 Jun 2025: Q2 2025
Total 13F shares, excl. options: 0
Holdings value: $0
Number of holders: 0
Number of sells: -57
Average sells %: -0%

Reported Shares, Excluding Options vs Price

Reported Value, Excluding Options

Total Investors

Significant Owners of Seres Therapeutics, Inc. - COMMON STOCK (MCRB)

Filer	Ownership	Change %	Holdings Value	Net Change	Nb Shares	Change %	Reporting Name	Report Period
FMR LLC	12.8%		$8,070,328		21,811,697		FMR LLC	31 Dec 2024

Institutional Holders of Seres Therapeutics, Inc. - COMMON STOCK (MCRB)

Period	Reported Shares, Excl. Options	Value, Excl. Options	Change	Puts Notional Value	Calls Notional Value	Price	Investors
2025 Q2	0	$0	-$42,948,707	$0	$0		0
2025 Q1	61,356,952	$42,953,245	-$1,247,523	$37,103	$72,171	$0.7001	59
2024 Q4	63,076,393	$52,464,054	-$352,556	$189,334	$2,453,586	$0.831	69
2024 Q3	63,393,718	$59,956,736	-$4,727,275	$445,772	$286,923	$0.9461	73
2024 Q2	69,128,714	$50,037,075	-$12,264,173	$335,801	$86,060	$0.7238	90
2024 Q1	85,696,040	$66,339,394	-$6,635,322	$367,010	$28,564	$0.7741	95
2023 Q4	89,516,690	$125,390,235	-$44,011,416	$302,540	$564,340	$1.4	102
2023 Q3	107,395,553	$255,568,518	-$20,522,942	$846,192	$1,180,718	$2.38	134
2023 Q2	112,314,465	$538,060,686	+$33,902,491	$2,821,138	$3,314,515	$4.79	138
2023 Q1	104,749,292	$593,914,430	-$2,181,787	$1,557,549	$1,586,466	$5.67	123
2022 Q4	105,102,786	$588,350,790	+$1,172,569	$679,840	$1,182,160	$5.6	124
2022 Q3	104,748,081	$671,698,908	+$112,916,464	$828,000	$1,320,000	$6.42	116
2022 Q2	90,405,204	$310,011,091	+$47,546,456	$627,000	$621,000	$3.43	120
2022 Q1	75,453,926	$537,205,498	-$11,701,157	$1,568,000	$2,894,000	$7.12	126
2021 Q4	77,171,897	$642,797,804	-$22,035,256	$2,205,000	$3,031,000	$8.33	142
2021 Q3	65,171,447	$453,652,143	-$219,705,817	$1,606,000	$3,013,000	$6.96	125
2021 Q2	66,583,026	$1,580,837,215	-$104,738,997	$5,026,000	$40,217,000	$23.85	139
2021 Q1	74,799,926	$1,540,145,276	+$72,736,725	$3,913,000	$26,204,000	$20.59	148
2020 Q4	71,626,700	$1,756,568,482	+$156,621,977	$5,216,000	$16,288,000	$24.5	147
2020 Q3	85,851,784	$2,426,035,273	+$414,565,041	$14,006,000	$66,942,000	$28.31	111
2020 Q2	71,964,573	$342,248,262	+$20,268,937	$2,855,000	$3,200,000	$4.76	90
2020 Q1	67,788,912	$241,901,175	+$6,595,767	$0		$3.57	74
2019 Q4	65,932,368	$227,461,925	+$4,749,334	$144,000	$0	$3.45	75
2019 Q3	64,313,390	$257,868,726	+$14,721,665	$156,000	$1,102,000	$4.01	72
2019 Q2	39,939,746	$128,358,021	+$60,626,039	$230,000	$1,447,000	$3.22	85
2019 Q1	21,002,266	$144,286,136	+$13,767,132	$230,000	$102,000	$6.87	76
2018 Q4	31,705,460	$143,306,876	-$2,231,121	$119,000	$0	$4.52	63
2018 Q3	19,333,726	$146,762,503	+$1,438,904	$93,000	$158,000	$7.59	67
2018 Q2	19,116,627	$164,501,153	-$2,874,809	$139,000	$398,000	$8.6	73
2018 Q1	32,343,237	$237,397,127	+$913,474	$125,000	$686,000	$7.34	76
2017 Q4	32,092,188	$325,414,128	+$13,231,493	$678,000	$881,000	$10.14	84
2017 Q3	18,094,829	$290,388,662	+$9,423,124	$8,803,000	$1,768,000	$16.04	78
2017 Q2	17,510,454	$197,876,628	-$3,586,958	$386,000	$1,240,000	$11.3	73
2017 Q1	30,512,429	$343,874,136	+$13,035,925	$283,000	$958,000	$11.27	78
2016 Q4	31,110,398	$307,998,792	-$7,897,755	$539,000	$202,000	$9.9	89
2016 Q3	31,171,671	$383,094,907	-$53,593,822	$2,579,000	$640,000	$12.29	93
2016 Q2	18,839,089	$547,325,562	+$54,055,120	$4,419,000	$1,142,000	$29.05	90
2016 Q1	30,947,144	$821,904,418	+$43,113,429	$1,437,000	$930,000	$26.56	76
2015 Q4	15,203,165	$533,480,616	+$51,097,629	$2,084,000	$3,698,000	$35.09	66
2015 Q3	13,811,455	$408,765,187	+$65,986,025		$1,583,000	$29.64	59
2015 Q2	11,381,595	$471,486,114	+$471,486,114			$41.5	45